PF-07275315 for Asthma
Trial Summary
What is the purpose of this trial?
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected.This study is seeking participants who:* Are 18 to 70 years old* Have had moderate-to-severe asthma for at least 12 months that is not well controlled* Have been taking their regular maintenance treatment(s) for asthma over the last 12 monthsAll participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.Participants will be involved in this study for about 9.5 months. During this time, they will have 10 visits at the study clinic.
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This trial is for people aged 18-70 with moderate-to-severe asthma that's been active for at least a year and isn't well-managed despite regular treatment. Participants will be involved in the study for about 9.5 months, with 10 clinic visits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive PF-07275315 or placebo as multiple shots in the clinic over the course of 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PF-07275315
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University